AstraZeneca (LON:AZN) had its price objective decreased by Jefferies Financial Group from GBX 6,400 ($83.63) to GBX 6,350 ($82.97) in a report released on Friday, Borsen Zeitung reports. Jefferies Financial Group currently has a hold rating on the biopharmaceutical company’s stock.
Several other brokerages have also issued reports on AZN. Liberum Capital reiterated a hold rating on shares of AstraZeneca in a research note on Friday, March 29th. Goldman Sachs Group reiterated a sell rating on shares of AstraZeneca in a research note on Monday, March 18th. Barclays reiterated an overweight rating on shares of AstraZeneca in a research note on Monday, March 11th. Deutsche Bank reiterated a buy rating and issued a GBX 6,900 ($90.16) price target on shares of AstraZeneca in a research note on Tuesday, February 26th. Finally, Shore Capital reiterated a buy rating on shares of AstraZeneca in a research note on Friday, March 29th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the company’s stock. AstraZeneca currently has a consensus rating of Hold and a consensus target price of GBX 6,480.56 ($84.68).
Shares of LON:AZN opened at GBX 6,089 ($79.56) on Friday. AstraZeneca has a 12 month low of GBX 5,110 ($66.77) and a 12 month high of GBX 6,540 ($85.46). The company has a current ratio of 0.75, a quick ratio of 0.57 and a debt-to-equity ratio of 179.66. The firm has a market cap of $79.87 billion and a P/E ratio of 32.05.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: What impact do institutional investors have on markets?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.